These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
302 related articles for article (PubMed ID: 36692485)
21. Resveratrol enhances the sensitivity of FL118 in triple-negative breast cancer cell lines via suppressing epithelial to mesenchymal transition. Yar Saglam AS; Kayhan H; Alp E; Onen HI Mol Biol Rep; 2021 Jan; 48(1):475-489. PubMed ID: 33389483 [TBL] [Abstract][Full Text] [Related]
22. Fangjihuangqi Decoction inhibits MDA-MB-231 cell invasion in vitro and decreases tumor growth and metastasis in triple-negative breast cancer xenografts tumor zebrafish model. Guo Y; Fan Y; Pei X Cancer Med; 2020 Apr; 9(7):2564-2578. PubMed ID: 32037729 [TBL] [Abstract][Full Text] [Related]
23. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer. Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870 [TBL] [Abstract][Full Text] [Related]
24. Suppression of KIF3A inhibits triple negative breast cancer growth and metastasis by repressing Rb-E2F signaling and epithelial-mesenchymal transition. Wang W; Zhang R; Wang X; Wang N; Zhao J; Wei Z; Xiang F; Wang C Cancer Sci; 2020 Apr; 111(4):1422-1434. PubMed ID: 32011034 [TBL] [Abstract][Full Text] [Related]
25. Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity. Cao D; Zhu GY; Lu Y; Yang A; Chen D; Huang HJ; Peng SX; Chen LW; Li YW Biomed Pharmacother; 2020 Sep; 129():110462. PubMed ID: 32768952 [TBL] [Abstract][Full Text] [Related]
26. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin. Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845 [TBL] [Abstract][Full Text] [Related]
27. Tweaking EMT and MDR dynamics to constrain triple-negative breast cancer invasiveness by EGFR and Wnt/β-catenin signaling regulation. Shome R; Ghosh SS Cell Oncol (Dordr); 2021 Apr; 44(2):405-422. PubMed ID: 33398673 [TBL] [Abstract][Full Text] [Related]
28. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Yoshida T; Ozawa Y; Kimura T; Sato Y; Kuznetsov G; Xu S; Uesugi M; Agoulnik S; Taylor N; Funahashi Y; Matsui J Br J Cancer; 2014 Mar; 110(6):1497-505. PubMed ID: 24569463 [TBL] [Abstract][Full Text] [Related]
29. PKMYT1 Promotes Epithelial-Mesenchymal Transition Process in Triple-Negative Breast Cancer by Activating Notch Signaling. Li B; Huang L; Ruan J Rev Invest Clin; 2024; 76(1):45-59. PubMed ID: 38442372 [TBL] [Abstract][Full Text] [Related]
30. Rubioncolin C, a natural naphthohydroquinone dimer isolated from Rubia yunnanensis, inhibits the proliferation and metastasis by inducing ROS-mediated apoptotic and autophagic cell death in triple-negative breast cancer cells. Li L; Wang J; Feng L; Fan J; Wang J; Tan N; Wang Z J Ethnopharmacol; 2021 Sep; 277():114184. PubMed ID: 33961996 [TBL] [Abstract][Full Text] [Related]
31. Ginsenoside 20(S)-protopanaxadiol inhibits triple-negative breast cancer metastasis in vivo by targeting EGFR-mediated MAPK pathway. Peng B; He R; Xu Q; Yang Y; Hu Q; Hou H; Liu X; Li J Pharmacol Res; 2019 Apr; 142():1-13. PubMed ID: 30735802 [TBL] [Abstract][Full Text] [Related]
32. USP22 Contributes to Chemoresistance, Stemness, and EMT Phenotype of Triple-Negative Breast Cancer Cells by egulating the Warburg Effect via c-Myc Deubiquitination. Li J; Gao R; Zhang J Clin Breast Cancer; 2023 Feb; 23(2):162-175. PubMed ID: 36528490 [TBL] [Abstract][Full Text] [Related]
33. Hyaluronic acid engrafted metformin loaded graphene oxide nanoparticle as CD44 targeted anti-cancer therapy for triple negative breast cancer. Basu A; Upadhyay P; Ghosh A; Bose A; Gupta P; Chattopadhyay S; Chattopadhyay D; Adhikary A Biochim Biophys Acta Gen Subj; 2021 Mar; 1865(3):129841. PubMed ID: 33412224 [TBL] [Abstract][Full Text] [Related]
34. A triple combination gemcitabine + romidepsin + cisplatin to effectively control triple-negative breast cancer tumor development, recurrence, and metastasis. Pattarawat P; Hunt JT; Poloway J; Archibald CJ; Wang HR Cancer Chemother Pharmacol; 2021 Sep; 88(3):415-425. PubMed ID: 34043046 [TBL] [Abstract][Full Text] [Related]
35. Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer. Liu J; Chen X; Ward T; Pegram M; Shen K Tumour Biol; 2016 Jul; 37(7):9825-35. PubMed ID: 26810188 [TBL] [Abstract][Full Text] [Related]
36. Elevated TGF-β1 and -β2 expression accelerates the epithelial to mesenchymal transition in triple-negative breast cancer cells. Kim S; Lee J; Jeon M; Nam SJ; Lee JE Cytokine; 2015 Sep; 75(1):151-8. PubMed ID: 26088755 [TBL] [Abstract][Full Text] [Related]
37. MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model. Bartholomeusz C; Xie X; Pitner MK; Kondo K; Dadbin A; Lee J; Saso H; Smith PD; Dalby KN; Ueno NT Mol Cancer Ther; 2015 Dec; 14(12):2773-81. PubMed ID: 26384399 [TBL] [Abstract][Full Text] [Related]
38. Schlafen12 Reduces the Aggressiveness of Triple Negative Breast Cancer through Post-Transcriptional Regulation of ZEB1 That Drives Stem Cell Differentiation. Al-Marsoummi S; Vomhof-DeKrey E; Basson MD Cell Physiol Biochem; 2019; 53(6):999-1014. PubMed ID: 31838790 [TBL] [Abstract][Full Text] [Related]
39. Pingxiao capsule inhibits lung metastasis of triple-negative breast cancer and sensitizes breast cancer to radiotherapy. Wenjuan T; Yu HU; Man Z; Mingzhi D; Tieming L; Ammar S; Yingzhuan Z; Yanmin Z J Tradit Chin Med; 2023 Oct; 43(5):897-905. PubMed ID: 37679977 [TBL] [Abstract][Full Text] [Related]
40. MicroRNA-543 inhibits the proliferation, migration, invasion, and epithelial-mesenchymal transition of triple-negative breast cancer cells via down-regulation of ACTL6A gene. Wang YL; Liang RH; Wang CY; Zhang RP; Wu SY; Han X; Zhang GL Clin Transl Oncol; 2022 Jan; 24(1):84-92. PubMed ID: 34181232 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]